CYP2B6
Also known as: 2B6GENO
Use
The CYP2B6 test is used to assess genetic risk of abnormal drug metabolism for CYP2B6 substrates. It may aid in drug selection and dose planning for medications metabolized by the CYP2B6 enzyme. Variants in the CYP2B6 gene can influence the pharmacokinetics of substrates, potentially predicting or explaining non-standard dose requirements, therapeutic failure, or adverse reactions.
Special Instructions
Counseling and informed consent are recommended for genetic testing. For NY patients, informed consent is required. Consent forms are available online.
Limitations
Only the targeted CYP2B6 variants will be detected by this test. Assumptions about phase and content are made to assign alleles. The test does not detect genetic or non-genetic factors that could affect the risk of therapeutic failure or adverse reactions with CYP2B6 substrates. This result does not replace the need for therapeutic drug or clinical monitoring. Diagnostic errors can occur due to rare sequence variations.
New York Approved
Methodology
PCR-based (PCR)
Biomarkers
LOINC Codes
- 66746-9
- 72882-4
- 79720-9
- 77202-0
- 11526-1
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1 mL
Container
Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or B)
Storage Instructions
Refrigerated.
Causes for Rejection
Plasma or serum. Specimens collected in sodium heparin or lithium heparin. Frozen specimens in glass collection tubes.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 1 week |
| Frozen | 1 month |